Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients
Introduction: Biosimilars are highly similar copies of previously approved original biologic medicines. Their introduction on the market may yield cost reduction. The aim of this study was to evaluate the perspectives of psoriasis patients on biosimilar medications. Materials and Methods: We conduct...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Ordem dos Médicos
2018-09-01
|
Series: | Acta Médica Portuguesa |
Subjects: | |
Online Access: | https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10127 |
id |
doaj-7baa7afa70194d7ea6f0d438f032f935 |
---|---|
record_format |
Article |
spelling |
doaj-7baa7afa70194d7ea6f0d438f032f9352020-11-25T00:33:49ZengOrdem dos MédicosActa Médica Portuguesa0870-399X1646-07582018-09-0131949650010.20344/amp.101274790Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese PatientsAlexandra Azevedo0Andreia Bettencourt1Manuela Selores2Tiago Torres3Serviço de Dermatologia: Centro Hospitalar do Porto. Porto.Instituto de Ciências Biomédicas Abel Salazar. Universidade do Porto. Porto.Serviço de Dermatologia: Centro Hospitalar do Porto. Porto. Instituto de Ciências Biomédicas Abel Salazar. Universidade do Porto. Porto.Serviço de Dermatologia: Centro Hospitalar do Porto. Porto. Instituto de Ciências Biomédicas Abel Salazar. Universidade do Porto. Porto.Introduction: Biosimilars are highly similar copies of previously approved original biologic medicines. Their introduction on the market may yield cost reduction. The aim of this study was to evaluate the perspectives of psoriasis patients on biosimilar medications. Materials and Methods: We conducted a 14 questions survey of psoriasis patients receiving biological therapy and followed-up in a dermatology department of a Portuguese tertiary care hospital. Results: From a total of 108 patients included, 70.4% of patients did not know the definition of biosimilar agent and 76.6% of patients showed partial or total interest in using a biosimilar drug. Nearly 80% of patients partially or totally agreed in using a biosimilar drug in order to reduce healthcare costs with psoriasis treatment. However, the lack of studies in the European population and in psoriatic patients led most of the patients (72.2% and 75.0%, respectively) to somewhat or completely oppose to the use of biosimilars. Demographic variables, household income and type of current biologic therapy did not affect patient preferences. Discussion: Despite of the unfamiliarity of the respondents with biosimilars, most patients seem receptive to their use. Nevertheless, there are two issues of concern: i) the use of biosimilars that are not tested in a European population, and ii) its approval for psoriasis without trials in this disease. Thus, an immediate need exists for patient education about biosimilars. Conclusion: Biosimilars may increase patient access to biologic therapies. Improved communication and the involvement of patients in decision-making regarding biosimilars may increase their acceptance in future.https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10127Biological TherapyBiosimilar PharmaceuticalsPsoriasis/therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Alexandra Azevedo Andreia Bettencourt Manuela Selores Tiago Torres |
spellingShingle |
Alexandra Azevedo Andreia Bettencourt Manuela Selores Tiago Torres Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients Acta Médica Portuguesa Biological Therapy Biosimilar Pharmaceuticals Psoriasis/therapy |
author_facet |
Alexandra Azevedo Andreia Bettencourt Manuela Selores Tiago Torres |
author_sort |
Alexandra Azevedo |
title |
Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients |
title_short |
Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients |
title_full |
Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients |
title_fullStr |
Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients |
title_full_unstemmed |
Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients |
title_sort |
biosimilar agents for psoriasis treatment: the perspective of portuguese patients |
publisher |
Ordem dos Médicos |
series |
Acta Médica Portuguesa |
issn |
0870-399X 1646-0758 |
publishDate |
2018-09-01 |
description |
Introduction: Biosimilars are highly similar copies of previously approved original biologic medicines. Their introduction on the market may yield cost reduction. The aim of this study was to evaluate the perspectives of psoriasis patients on biosimilar medications.
Materials and Methods: We conducted a 14 questions survey of psoriasis patients receiving biological therapy and followed-up in a dermatology department of a Portuguese tertiary care hospital.
Results: From a total of 108 patients included, 70.4% of patients did not know the definition of biosimilar agent and 76.6% of patients showed partial or total interest in using a biosimilar drug. Nearly 80% of patients partially or totally agreed in using a biosimilar drug in order to reduce healthcare costs with psoriasis treatment. However, the lack of studies in the European population and in psoriatic patients led most of the patients (72.2% and 75.0%, respectively) to somewhat or completely oppose to the use of biosimilars. Demographic variables, household income and type of current biologic therapy did not affect patient preferences.
Discussion: Despite of the unfamiliarity of the respondents with biosimilars, most patients seem receptive to their use. Nevertheless, there are two issues of concern: i) the use of biosimilars that are not tested in a European population, and ii) its approval for psoriasis without trials in this disease. Thus, an immediate need exists for patient education about biosimilars.
Conclusion: Biosimilars may increase patient access to biologic therapies. Improved communication and the involvement of patients in decision-making regarding biosimilars may increase their acceptance in future. |
topic |
Biological Therapy Biosimilar Pharmaceuticals Psoriasis/therapy |
url |
https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/10127 |
work_keys_str_mv |
AT alexandraazevedo biosimilaragentsforpsoriasistreatmenttheperspectiveofportuguesepatients AT andreiabettencourt biosimilaragentsforpsoriasistreatmenttheperspectiveofportuguesepatients AT manuelaselores biosimilaragentsforpsoriasistreatmenttheperspectiveofportuguesepatients AT tiagotorres biosimilaragentsforpsoriasistreatmenttheperspectiveofportuguesepatients |
_version_ |
1725314774063906816 |